Mitotech is focused on the rapid development of small molecule therapies to target excessive mitochondrial ROS (mtROS) and protect mitochondrial bioenergetics. Our novel therapeutic approach has generated Visomitin®, a promising drug candidate for the treatment of numerous ophthalmic indications with major unmet medical need.
